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Genomes encode proteins and RNAs responsible for biosynthesis, biodegradation, and 
transport of additional molecules, such as small metabolites, lipids and glycans. This fact 
may indicate that the genomic DNA sequence specify all cellular functions. In practice, 
however,  inferring higher-level systemic functions of a cell or organism needs more than 
solely the genomic information. We are developing bioinformatics methods to integrate 
 different types of data and knowledge on various aspects of the biological systems towards 
basic understanding of life as a molecular interaction/ reaction system and also to-
ward  practical applications in medical and pharmaceutical sciences.
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KEGG MEDICUS for Translational 
Bioinformatics
KEGG MEDICUS is a new resource for diseases, drugs 
and environmental substances, aiming to bring the genomic 
revolution to society. In KEGG, diseases are perturbed 
states in the molecular system and drugs are perturbants to 
the molecular system. Our knowledge on perturbed 
 molecular system (network) is captured and presented as 
disease pathway maps in KEGG PATHWAY database. 
Other disease related knowledge on genetic and environ-
mental perturbation is stored in KEGG DISEASE, listing 
known genetic factors (disease genes), environmental 
 factors, diagnostic markers, and therapeutic drugs. All the 
marketed drugs in Japan, the OTC dugs as well as the 
 prescription drugs, are fully represented in KEGG DRUG 
based on the chemical structures and/or the chemical 
 components associated with target, metabolizing enzyme 
and other molecular network information. They are also 
integrated with the package insert information (labels 
 information) that is applied to the adverse drug-drug 
 interaction analysis described below. Health promoting 
and damaging substances such as crude drugs, essential 
oils, and other chemical substances are also collected and 
stored in KEGG ENVIRON with chemical component, 
efficacy and source species information whenever appli-
cable. KEGG MEDICUS integrates the information in 
KEGG DISEASE, KEGG DRUG, KEGG ENVIRON, as 
well as other KEGG and outside databases in terms of 
 genome-based biological systems (molecular network) 
 information. As an attempt to integrate with outside 
 resources, somatic mutation data obtained from Sanger 
Institute’s COSMIC (Catalog Of Somatic Mutation In 
Cancer) database are mapped against KEGG cancer path-
way and visualized in 3D map viewer (Figure 1).
System Wide Analysis of Adverse Drug-drug 
Interactions
Co-administration of multiple drugs can cause adverse 
effects. It is becoming more important to provide a 
 comprehensive view of drug-drug interactions among all 
the drugs in use, as well as a computational method to 
identify potential interactions. We extracted 1,306,565 
known drug-drug interactions from all the package inserts 
of prescription drugs marketed in Japan. They were re-
duced to 45,180 interactions involving 1352 drugs (active 
ingredients) identified by the D numbers in the KEGG 
DRUG database, of which 14,441 interactions involving 
735 drugs were linked to the same drug-metabolizing 
 enzymes and/or overlapping drug targets. The interactions 
with shared targets were classified into three types: acting 
on the same target, acting on different but similar targets 
in the same protein family, and acting on different targets 
assigned to the same pathway. For the rest of the extracted 
interaction data, we attempted to characterize interaction 
patterns using drug group information. The drug groups 
were defined by the Anatomical Therapeutic Chemical 
(ATC) classification system, where the high-resolution 
network at the D number level is progressively reduced to 
a low-resolution global network. Based on this study we 
have developed a drug-drug interaction retrieval system 
in the KEGG DRUG database, which may be used for 
both searching against known drug-drug interactions and 
predicting potential interactions.
Figure 1. Cancer pathway map with somatic mutation frequency ob-
served in colorectal cancer. The green boxes correspond to genes and the 
height or color-shading of the bar associated with each gene corresponds 
to the mutation frequency. Figure 2. Drug interaction networks in the drug hierarchy.
